key: cord-1034424-bsosh4dt authors: Sharma, A.; Misra-Herbert, A. D.; Mariam, A.; Milinovich, A.; Kattan, M. W.; Pantalone, K. M.; Rotroff, D. M. title: Impacts of COVID-19 on glycemia and risk of diabetic ketoacidosis date: 2022-03-10 journal: nan DOI: 10.1101/2022.03.08.22272041 sha: 7fae3b898ee486fc04b8e357d3f12fd8bcbf08ea doc_id: 1034424 cord_uid: bsosh4dt Background Reports indicate that COVID-19 may impact pancreatic function and increase type 2 diabetes (T2D) risk, although real-world COVID-19 impacts on HbA1c and T2D are unknown. We tested whether COVID-19 increased HbA1c, risk of T2D, or diabetic ketoacidosis (DKA). Methods We compared pre- and post-COVID-19 HbA1c, and risk of developing T2D in a large real-world clinical cohort of 8,755 COVID-19(+) patients and a matched control cohort of 11,998 COVID-19(-) patients. We investigated if DKA risk was modified in COVID-19(+) patients with type 1 diabetes (T1D) (N=704) or T2D (N=22,904), or by race and sex. Findings We observed a statistically significant, albeit clinically insignificant, HbA1c increase post-COVID-19 (all patients {Delta}HbA1c=0.06%, P<.001; with T2D {Delta}HbA1c=0.1%; P<.001), and no increase among COVID-19(-) patients (P>.05). COVID-19(+) patients were 40% more likely to be diagnosed with T2D compared to COVID-19(-) patients (P<.001) and 28% more likely to be diagnosed with T2D for the same HbA1c change as COVID-19(-) patients (P<.001). COVID-19(+) patients with T2D on insulin were 34% more likely to develop DKA compared to COVID-19(-) patients on insulin (P<.05), and COVID-19(+) Black patients with T2D displayed disproportionately increased DKA risk (HR:1.63, P=.007). There was no significant difference in DKA risk between COVID-19(+) and COVID-19(-) patients with T1D. Interpretation DKA risk is increased in T2D patients on insulin and in Black patients with T2D after COVID-19 infection.T2D risk is greater in COVID-19(+) patients for the same HbA1c increase in COVID-19(-) patients, indicating that T2D risk attributed to COVID-19 may be due to increased recognition during COVID-19 management. SARS-CoV-2 was recently demonstrated in two separate studies to infect pancreatic β cells in vitro 1, 2 , raising concerns as to whether SARS-CoV-2 infection (COVID-19) may impact glycemic control 3 . Type 2 diabetes (T2D) is an established risk factor for COVID-19 severity and pre-infection hemoglobin A1c (HbA1c) was shown to be an important predictor of COVID-19 severity in multiple studies [4] [5] [6] . Although HbA1c has been reported as an important risk factor for COVID-19, the impact of COVID-19 on HbA1c is unknown [6] [7] [8] . Previous studies have indicated that COVID-19 may increase HbA1c post-infection, but the cohorts were small and lacked COVID-19(-) controls for comparison 9, 10 . Furthermore, case studies of patients developing insulin-dependent diabetes and diabetic ketoacidosis (DKA) after COVID-19 have been reported 11, 12 . and a reduction in DKA hospitalization in patients with Type 1 diabetes (T1D), during the course of the COVID-19 pandemic 13 . However, this study also lacked a negative control population to determine whether the risk was increased in patients that were infected with SARS-CoV-2 or was due to other factors. Here, we present the first evidence of COVID-19 impacts on HbA1c in a large, real-world clinical cohort of >8,500 patients by testing the following hypotheses 1) COVID- 19 In order to evaluate the risk of DKA onset post-COVID-19 infection, we identified two sub-cohorts of patients with pre-existing T1D. Patients with a prior history of DKA at any time point prior to their COVID-19 test were excluded from this cohort. Patients were determined to have T2D based on a modified form of the eMERGE algorithm, as described in Kho et al. 14 The eMERGE algorithm is designed to determine, with a high degree of specificity, which patients in an electronic health record have T2D based on a combination of ICD codes, medications, and laboratory values (e.g., blood glucose), and excludes patients with T1D. However, the original eMERGE algorithm utilized only ICD-9 codes, so the algorithm used here was modified to also include ICD-10 codes. T2D control patients were those that did not meet the eMERGE T2D criteria and had no history T1D. Patients were considered to have T1D as per the Phenotype Algorithm for T1D in the eMERGE Phase-IV program 15 . The T2D(+) cohort was further stratified into groups based on baseline insulin usage (yes or no), race and sex for DKA outcome assessment. Additionally, outcome of hyperosmolar hyperglycemic syndrome (HHS) was also assessed in T2D(+) cohort excluding patients with a prior history of HHS at any time prior to their COVID-19 test. The following outcomes were investigated for association with HbA1c in COVID-19(+) patients: T2D onset (based on eMERGE algorithm described above), hospitalization, admission to intensive care units (ICU), assisted breathing requirements, ventilation, and mortality. Additionally, DKA diagnosis was determined based on the ICD9/10 codes (ICD9:250.1x, ICD10:E10.1x, E11.1x). HHS was determined based on the ICD9/10 codes (ICD9:250.2x, ICD10:E11.0x). Statistical analyses were performed using R, v4.1.1 16 . Pre-and post-COVID-19 test HbA1c values were compared between patients 1) with and without T2D, and 2) with and without COVID-19(+) test results using paired Student's t-tests. Logistic regression was employed to test for differences in new T2D diagnoses among COVID-19(+) and COVID-19(-) patients. HbA1c was tested for association with time-tohospitalization, ventilation, assisted breathing, ICU admission, mortality, T2D onset using Cox proportional hazards (CoxPH) models. Mortality was used as a competing risk in all CoxPH models, except for when mortality was the outcome. Restricted cubic spline CoxPH models were used to investigate non-linear relationships between HbA1C and outcomes of interest 17 (Supplemental Figures 3-6) . Age, sex, race, BMI, pre-COVID-19 HbA1c, Charlson comorbidity score 18 , medications (including anti-diabetes therapies prior to infection and during the study window), prior comorbidities, the time intervals between the COVID-19 test and the pre-test HbA1c and the post-test HbA1c were used as model covariates for all analyses. For DKA and HHS onset, when not stratified by insulin use, we adjusted for insulin at baseline, in addition to the other covariates described above. Furthermore, Kaplan-Meier plots were also used to visualize the associations between DKA onset and COVID-19 test status in R using packages survminer and survival 19, 20 . All reported P have been adjusted for multiple Compared to COVID-19(-) patients, a 0.09% increase in post-infection HbA1c was observed in COVID-19(+) patients with T2D (P<.001) (Supplemental Figure 1c) . In patients without T2D, a clinically insignificant increase HbA1c of 0.05% in COVID-19(+) patients compared to COVID-19(-) patients (P<.001) was observed (Supplemental Figure 1c) . Furthermore, the 0.09% HbA1c increase observed in patients with T2D was statistically greater than patients without T2D (0.05%) (P=.002). Comparable results were obtained after restricting the pre-COVID-19 test HbA1c time interval from 12 months to 6 and 3 months (data not shown). Although well reported in the literature, we also investigated whether pre-COVID-19 HbA1c was associated with COVID-19 severity in our cohort (i.e., hospitalization, ventilation, assisted breathing, ICU admission). In the COVID-19(+) cohort of patients with T2D, we identified a significant positive association between pre-COVID-19 HbA1c Pre-COVID-19 HbA1c was a significant risk factor for receiving a T2D diagnosis in COVID-19(+) patients (HR=4.08, P<.001) and COVID-19(-) patients (HR=1.34, P<.001), indicating that higher pre-COVID-19 test HbA1c increased risk of receiving a T2D diagnosis regardless of COVID-19 status (Figure 2A) . Similarly, risk of T2D onset was higher in individuals with greater HbA1c increase in COVID-19(+) (HR=1.74, P<.001) and COVID-19(-) patients (HR=1.46, P<.001) ( Figure 2D ). However, COVID-19(+) patients were also more likely to receive a T2D diagnosis post-infection (N=326/2,433) compared to COVID-19(-) (N=380/6,594) patients (OR=1.4, P<.001). Interestingly, the likelihood of being diagnosed with T2D, per unit change in HbA1c, was also higher for COVID-19(+) patients than COVID-19(-) patients. Using the restricted cubic spline non-linear CoxPH models demonstrated similar association patterns (Supplemental Figure 3) . Furthermore, restricting the pre-COVID-19 test HbA1c time interval from 12 months to 6 and 3 months resulted in similar significant trends for T2D onset for both COVID-19(+) as well as COVID-19(-) control group (data not shown). We evaluated the risk of DKA onset post-COVID-19 infection, in two sub-cohorts of patients with pre-existing T1D (n=701) and (T2D) (n=21,830) out of the total COVID-19(+) (n=81,093) and COVID-19(-) population (n=153,034). In patients with T1D, there was no statistically significant difference in risk of developing DKA between those that were COVID-19(+) and those that were COVID-19(-) (HR=0.978, P=.48) ( Figure 3 ). However, patients with T2D that were COVID-19(+) had a 35% greater risk of DKA compared to patients with T2D that were COVID-19(-) (HR=1.35, P=.002) (Figure 3 ). Patients with T2D that were on insulin were at increased risk of DKA compared to patients not on insulin regardless of COVID-19 testing status ( Figure 4A ,B). However, All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 10, 2022. ; https://doi.org/10.1101/2022.03.08.22272041 doi: medRxiv preprint stratification of patients with T2D by insulin usage, also revealed that COVID-19(+) patients with T2D on insulin had a 34% greater risk of DKA than COVID-19(-) patients on insulin (HR=1.34, P=.02) (Figure 3 ). The risk of DKA between patients with T2D that were not on insulin was not significantly different between those that were COVID-19(+) and those that were COVID- were more than twice as likely to be diagnosed with DKA compared to White patients with T2D (HR=2.32, P=1.16x10 -5 ) (Fig. 4A ). There was no significant difference in DKA risk between males and females with T2D that were COVID-19(+) (HR=1.02, P=.88) or COVID-19(-) (HR=1.00, P=.89) ( Figure 4A ,C). The increase observed in males with T2D that were COVID-19(+) compared to those that were COVID-19(-) was not statistically significant (HR=1.80, P=.30). However, females with T2D demonstrated a significantly higher risk for DKA if COVID-19(+) (HR=1.42, P=.03) ( Figure 3A ). Therefore, although there was no difference in risk of DKA between males and females that were COVID-19(+) ( Figure 4A ), there was a relative increase in risk of females that were COVID-19(+) to those that were COVID-19(-) (Fig. 3,4A ). The impact of COVID-19 on HbA1c and glycemic impairment is still poorly understood. Yang et al. demonstrated that human pluripotent stem cell-derived and adult human pancreatic β cells were permissive to SARS-CoV-2 infection in vitro 1 . This was further supported by findings that SARS-CoV-2 was capable of infecting human pancreatic islets ex vivo and impaired insulin secretion in an in vitro model system 2 . Further raising concerns that COVID-19 might impair glycemic control, Montefusco et al. found that 46% of 551 patients hospitalized for COVID-19(+) were hyperglycemic, but this analysis lacked a COVID-19(-) population for comparison 10 . A meta-analysis of 179 patients showed an increase in blood glucose in COVID-19(+) patients that failed to reach statistical significance 9 . Other forms of glycemic impairment have also been reported-a case study recently reported a patient that developed by autoantibodynegative insulin-dependent diabetes (type 1B subtype) that presented as DKA several weeks post-COVID-19 infection 12 . A second case study of an otherwise healthy patient developing DKA while infected with SARS-CoV-2 was also reported, although the autoantibody status of this patient was not reported 11 . Although these studies suggest the potential for COVID-19 to disrupt glycemic response, no large controlled clinical studies have been conducted to determine the extent of this risk in patients diagnosed with COVID-19. This study improves upon limitations of previous studies by (1) utilizing a large cohort of 8,755 COVID-19(+) All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 10, 2022. ; https://doi.org/10.1101/2022.03.08.22272041 doi: medRxiv preprint patients, (2) investigating pre-and post-infection HbA1c levels with respect to T2D status, and (3) including a large, matched cohort of 11,998 COVID-19(-) patients for comparison. Our findings indicate that there is an approximate 0.1% increase postinfection HbA1c among patients with and without T2D, which is statistically significant but clinically insignificant (Figure 1a ). Although COVID-19(+) patients were 40% more likely to be diagnosed with T2D compared to COVID-19(-) patients (P<.001), we also found that COVID-19(+) patients were 274% more likely to get diagnosed with T2D for the same pre-COVID-19 test HbA1c and 28% more likely for the same increase in HbA1c after their COVID-19 test (Figure 1c ) (P<.001). A possible explanation for this is that COVID-19(+) patients are receiving more intensive care that results in better identification of patients that have underlying T2D. Interestingly, among patients with pre-existing T2D, we observed a 35% increased risk of developing DKA in COVID-19(+) patients compared to COVID-19(-) patients (P=.002). Importantly, this observation seems to be driven in part by patients that were on insulin at the time of their COVID-19 diagnosis (HR=1.34, P=.02), whereas the increase in DKA in patients with T2D that were not on insulin failed to reach significance (HR:1.30, P=.29) ( Figure 4) . Notably, COVID-19 infection did not increase DKA in patients with pre-existing T1D. A previous study found that hospital admissions for DKA increased compared to preceding years in patients with T2D during the COVID-19 pandemic but decreased for patients with T1D over the same time period 13 . It has been hypothesized that the difference in DKA incidence between patients with T1D and T2D may be due to the training of patients with T1D to titrate insulin based on glucose levels, whereas patients with T2D may check their glucose levels more infrequently, resulting in higher insulin levels 13 . We also observed a higher risk of DKA onset in the Black COVID-19(+) patients with T2D compared to the Black COVID-19(-) patients with T2D (HR=1.632, P=.007), a relationship not observed in White patients (Figures 3,4 ). In addition, there was a relative increase in risk for DKA of females with T2D that were COVID-19(+) compared to females with T2D that were COVID-19(-) (HR: 1.42, P=.03), which was not observed in males (HR: 1.18, P=.30) (Figures 3, 4) . These findings, in particular the findings of increased DKA in patients with T2D that are Black and those that are on insulin, which are consistent across studies, indicate that increased awareness is needed for DKA in these patient populations if infected with COVID-19. As with any study, there are limitations that should be considered during the interpretation of the findings. To evaluate a large cohort of patients, we included patients with a HbA1c measurement for up to 12 months prior to their COVID-19 test. Although we adjusted for the time between HbA1c and COVID-19 testing, comorbid conditions, and medications during this period, it is possible that medication changes or other factors during the 12 months impacted HbA1c. To address this, we also evaluated the results using three-and six-month intervals, which yielded consistent results, indicating that these factors are unlikely to have a material impact on the analysis. Although consistent criteria were applied to the selection of COVID-19(+) and COVID-19(-) patients, HbA1c values were not available for many patients in the COVID-19 registry, and care was disrupted during the pandemic, which may bias the population available for inclusion in this study. Furthermore, this was a single-center study and patients may have received care at a different institution resulting in medical histories All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 10, 2022. ; unavailable for this study. Additional studies at other sites and with longer follow-up data on HbA1c levels are needed to verify our results. In conclusion, we observed a statistically significant, but clinically insignificant increase in HbA1c post-COVID-19 infection, and the increased likelihood of receiving a T2D diagnosis post-COVID-19 infection may be due to the increased care provided to these patients. Notably, in this large cohort of patients that were COVID-19(+), the risk of DKA was significantly higher in patients with pre-existing T2D overall and those on baseline insulin and those that are Black. Additional research is required to understand the pathogenesis of COVID-19 infection and DKA in patients with T2D, and additional clinical awareness is needed for DKA in these patient populations. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Data related to this manuscript will be made available upon request in adherence with transparency conventions in medical research and through requests to the corresponding author. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 10, 2022. ; (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. A) * * * + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + ++++ ++ + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + ++ + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + ++ + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + +++ + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + ++ + ++ + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + ++ + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + ++ + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + ++ + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + ++ + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 10, 2022. Reference HbA1c change = 0 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 10, 2022. ; Supplementary Figure 4 : Non-parametric estimates of the dependence of all-time risk of (A) hospitalization, (B) assisted breathing, (C) ventilation, and (D) admission to ICU on baseline A1C among the COVID-19(+) patients with Type-2 Diabetes diagnosis. The plots were generated using restricted cubic splines implemented in Cox proportional hazard models using smoothHR package in R (2). Reference HbA1c = 6.5 Ln [HR, 95% con dence interval] Reference HbA1c = 6.5 Reference HbA1c = 6.5 Reference HbA1c = 6.5 Smooth log hazard ratio for Pre-COVID-19 HbA1c Smooth log hazard ratio for Pre-COVID-19 HbA1c Smooth log hazard ratio for Pre-COVID-19 HbA1c Pre-COVID-19 HbA1c Pre-COVID-19 HbA1c Pre-COVID-19 HbA1c All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 10, 2022. ; https://doi.org/10.1101/2022.03.08.22272041 doi: medRxiv preprint Supplementary Figure 5 : Non-parametric estimates of the dependence of risk of allcause mortality on pre-COVID-19 test HbA1c in (A) COVID-19(+) patients with T2D diagnosis, (B) COVID-19(-) patients with T2D diagnosis, (C) COVID-19(+) patients without T2D diagnosis, and (D) COVID-19(-) patients without T2D diagnosis. The reference HbA1c values for T2D(+) cohort was set to 6.5 and for T2D(-) patients was set to 5. The plots were generated using restricted cubic splines (rcs) implemented in Cox proportional hazard models using smoothHR package in R (2). Smooth log hazard ratio for Pre-COVID-19 HbA1c Reference HbA1c = 6.5 Reference HbA1c = 5 Reference HbA1c = 5 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 10, 2022. ; https://doi.org/10.1101/2022.03.08.22272041 doi: medRxiv preprint Supplementary Figure 6 : Non-parametric estimates of the dependence of risk of allcause mortality on post-COVID-19 test HbA1c in (A) COVID-19(+) patients with T2D diagnosis, (B) COVID-19(-) patients with T2D diagnosis, (C) COVID-19(+) patients without T2D diagnosis, and (D) COVID-19(-) patients without T2D diagnosis. The reference HbA1c change was set to 0. The plots were generated using restricted cubic splines (rcs) implemented in Cox proportional hazard models using smoothHR package in R (2). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted March 10, 2022. ; https://doi.org/10.1101/2022.03.08.22272041 doi: medRxiv preprint A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids SARS-CoV-2 infects human pancreatic β cells and elicits β cell impairment Practical recommendations for the management of diabetes in patients with COVID-19 Haemoglobin A1c is a predictor of COVID-19 severity in patients with diabetes Type-2 Diabetes as a Risk Factor for Severe COVID-19 Infection Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes Remote Glucose Monitoring of Hospitalized, Quarantined Patients With Diabetes and COVID-19 The clinical characteristics and outcomes of patients with diabetes and secondary hyperglycaemia with coronavirus disease 2019: A single-centre, retrospective, observational study in Wuhan The Impact of COVID-19 on Blood Glucose: A Systematic Review and Meta-Analysis Acute and long-term disruption of glycometabolic control after SARS-CoV-2 infection Diabetic ketoacidosis precipitated by Covid-19 in a patient with newly diagnosed diabetes mellitus Autoantibody-negative insulin-dependent diabetes mellitus after SARS-CoV-2 infection: a case report Temporal trends in emergency admissions for diabetic ketoacidosis in people with diabetes in England before and during the COVID-19 pandemic: a population-based study Use of diverse electronic medical record systems to identify genetic risk for type 2 diabetes within a genome-wide association study R: A language and environment for statistical computing Smooth Hazard PhD 1,4,5,# 2. Department of Quantitative Health Sciences Cleveland Clinic Lerner College of Medicine Use of diverse electronic medical record systems to identify genetic risk for type 2 diabetes within a genome-wide association study Smooth Hazard We would like to acknowledge the many people that worked to establish the Cleveland COVID-19 data-registry and their efforts to make this valuable resource available to investigators.